Get the Stockscreener App
1.39
0.00%
0.00
Erasca Inc stock is traded at $1.39, with a volume of 537.40K.
It is up +0.00% in the last 24 hours and up +16.32% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$1.39
Open:
$1.38
24h Volume:
537.40K
Relative Volume:
0.34
Market Cap:
$447.59M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-1.6951
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
-12.03%
1M Performance:
+16.32%
6M Performance:
-55.73%
1Y Performance:
-29.08%
1-Day Range:
$1.355
$1.46
1-Week Range:
$1.205
$1.57
52-Week Range:
$1.01
$3.45
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
1.39 | 447.59M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
MetLife Investment Management LLC Has $283,000 Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca to Present at the Bank of America Securities Health Care Conference - TradingView
Invesco Ltd. Acquires 11,290 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Barclays PLC Boosts Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Wells Fargo & Company MN Sells 73,262 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
HC Wainwright Reaffirms Buy Rating for Erasca (NASDAQ:ERAS) - Defense World
Holdings of Erasca Inc (ERAS) are aligned with the stars - Sete News
Analyze Erasca Inc (NASDAQ: ERAS) Before Investing. - Stocksregister
Erasca Inc (ERAS)’s stock price range in the last year - uspostnews.com
Legal & General Group Plc Buys 64,574 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca (ERAS) Showcases Innovative RAS-Targeting Treatments at C - GuruFocus
Erasca presents new RAS-targeting franchise data at AACR meeting - TipRanks
XTX Topco Ltd Purchases Shares of 55,361 Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting - The Manila Times
New Cancer Drug Data: Erasca's RAS Inhibitors Show Best-in-Class Potential at AACR 2025 - Stock Titan
Erasca Inc (NASDAQ: ERAS) Shares Are Down -44.22% Year To Date. - Marketing Sentinel
Checking in on Erasca Inc (ERAS) after recent insiders movement - knoxdaily.com
Erasca, Inc. (NASDAQ:ERAS) Receives $4.83 Consensus Price Target from Brokerages - Defense World
Erasca, Inc: Carving A Different Niche In RAS Signaling (NASDAQ:ERAS) - Seeking Alpha
Check out these key findings about Erasca Inc (ERAS) - Sete News
Analytical Overview: Erasca Inc (ERAS)’s Ratios Tell a Financial Story - DWinneX
Erasca Inc (ERAS) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
ERAS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Geode Capital Management LLC Grows Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
JPMorgan Chase & Co. Lowers Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Is Erasca Inc. (NASDAQ:ERAS) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance
Wellington Management Group LLP Acquires New Stake in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Vanguard Group Inc. Sells 614,840 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Vanguard Group Inc. Has $31.81 Million Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - The AM Reporter
KLP Kapitalforvaltning AS Makes New $69,000 Investment in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Shares Acquired by American Century Companies Inc. - Defense World
Erasca stock hits 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa
Erasca stock hits 52-week low at $1.02 amid market challenges - Investing.com
Erasca Slides As Insider Purchases Lose Another US$84k - Yahoo Finance
Erasca (NASDAQ:ERAS) vs. Merck KGaA (OTCMKTS:MKGAF) Head-To-Head Contrast - Defense World
Erasca Inc (NASDAQ: ERAS) Stock Sentiment: What’s Wall Street Saying? - stocksregister.com
Thrivent Financial for Lutherans Sells 29,263 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Teacher Retirement System of Texas Buys 12,345 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca Insiders Lose Out As Stock Sinks To US$1.21 - simplywall.st
Erasca stock hits 52-week low at $1.23 amid market challenges - Investing.com India
Erasca stock hits 52-week low at $1.23 amid market challenges By Investing.com - Investing.com South Africa
Erasca (NASDAQ:ERAS) Coverage Initiated by Analysts at Raymond James - MarketBeat
Erasca, Inc. (NASDAQ:ERAS) Shares Bought by Swiss National Bank - Defense World
Erasca (NASDAQ:ERAS) Now Covered by Analysts at Raymond James - Defense World
Raymond James sets $5 target for Erasca stock, cites valuation gap By Investing.com - Investing.com South Africa
Raymond James Initiates Coverage of Erasca (ERAS) with Outperform Recommendation - Nasdaq
This Spotify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Raymond James sets $5 target for Erasca stock, cites valuation gap - Investing.com India
Raymond James Initiates Erasca at Outperform With $5 Price Target - MarketScreener
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):